Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03577041
Other study ID # PI2017_843_0009
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2019
Est. completion date July 1, 2023

Study information

Verified date February 2023
Source Centre Hospitalier Universitaire, Amiens
Contact Sophie BRYSELBOUT, Dr
Phone 33 3 22 08 92 19
Email bryselbout.sophie@chu-amiens.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.


Description:

Numerous clinical trials have shown the effectiveness of Bevacizumab in the treatment of neovascular AMD as well that non-inferiority compared to Ranibizumab in terms of clinical efficacy at 1 year on visual acuity measured by the ETDRS scale of patients with neovascular AMD. Regarding general tolerance, a recent meta-analysis including a large number of patients did not find any difference in systemic serious adverse reactions, neither any new special signal of tolerance with Bevacizumab. Concerning eye tolerance, there is no evidence of difference significant. Medico-economic analyzes carried out in other countries, as the United States or Brazil, have shown that Bevacizumab is cost-effective compared to Ranibizumab in AMD Neovascular. The cost-utility analysis of the different methods of care patients with AMD will rely on the construction of a self-centered model built from: data available in natural history literature AMD in the absence of treatment; results of the network meta-analysis comparing effectiveness and tolerance of different strategies to assess; available data on adherence and persistence of treatments; pharmacovigilance data on the occurrence of side effects. This analysis benefits from two related studies: - Micro-costing, multicenter study of the preparation of intravitreal injections of Bevacizumab hospital pharmacy. - Multicenter, prospective evaluation, cross-section, quality of life data and patient cost depending on the level of visual acuity. According to the recommendations, at the beginning of the treatment, after the diagnosis of neovascular naive AMD, the patient will benefit from a fixed regimen of treatment by intravitreous injection of Bevacizumab or Ranibizumab or Aflibercept renewed every month for 3 months. Before each Intra-vitreous injection, the patient will be reviewed in consultation to collect the occurrence of events adverse reactions related to the injection of one of the three products. After 3 months, the monthly intra-vitreous injections will be left to the appreciation of the investigator. The follow-up of the patients, during a specialized consultation will be spread out over 6 months according to the rhythm of a consultation by months and then 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied), - Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept, - Patient using effective contraception if he is of childbearing age - Patient informed and not having made his opposition to the research, - Patient under social security scheme. Exclusion Criteria: - Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye, - Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept, - Aphakia in the studied eye, - Fibrosis or retrofoveolar retinal atrophy of the eye studied, - Tearing of the pigment epithelium reaching my macula of the studied eye, - Choroidal neovascularization unrelated to AMD, - Diabetic retinopathy and / or diabetic maculopathy proven, - Glycated hemoglobin greater than 12%, - Known hypersensitivity to pharmaceutical agents used, - Pregnant or lactating women, - Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis, - Active or suspected ocular or periocular infection, - Intraocular pressure> 25mmHg despite two hypotonizing treatments in eye drops, - Patient under tutorship or curatorship or private public law.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHU Amiens Amiens

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration Using a probabilistic Markov model 12 months
Secondary Micro-costing type evaluation of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital. Costs of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital (flasks of Bevacizumab, materials, personal, infrastructure, conservation) 12 months
Secondary Quality of life coefficient: HUI 3 questionnaire Quality of life will be estimated using the HUI 3 questionnaire and corresponding value-set 12 months
See also
  Status Clinical Trial Phase
Completed NCT01694680 - Intervention Trial in Early Age-related Macular Degeneration N/A
Completed NCT01224847 - Intravitreal Injection Anesthesia - Comparison of Different Topical Agents N/A
Withdrawn NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) Phase 3
Completed NCT05037396 - Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
Completed NCT00647439 - Genetics and Markers of Degenerative and Inflammatory Eye Diseases
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT03690505 - Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place N/A
Completed NCT05082415 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
Completed NCT02445313 - Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
Recruiting NCT00354445 - A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Phase 4
Completed NCT05111743 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Terminated NCT02398500 - Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT05110209 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Completed NCT05146687 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Not yet recruiting NCT05780931 - Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
Recruiting NCT04292080 - Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02022540 - Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Phase 1
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A